首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Efficacy and safety of a combination therapy of atorvastatin and krill oil versus atorvastatin and niacin in dyslipidemia: a randomized, open, and comparator study
【24h】

Efficacy and safety of a combination therapy of atorvastatin and krill oil versus atorvastatin and niacin in dyslipidemia: a randomized, open, and comparator study

机译:阿托伐他汀与磷虾油联合使用阿托伐他汀与烟酸联合治疗血脂异常的疗效和安全性:一项随机,开放和比较研究

获取原文
           

摘要

Background: Atherosclerotic cardiovascular disease is a major health problem, with CAD being the leading cause of mortality. Epidemiologic data strongly associate high CAD risk to elevated total and LDL cholesterol and low levels of HDL cholesterol. Combination therapy is often required to achieve multiple lipid treatment goals, and ≥50% reduction in low-density lipoprotein. Niacin/statin combination therapy may promote the cost-effective achievement of OLVs in several at-risk patient populations. Krill oil is extracted from Antarctic krill, Euphausia superba, a zooplankton crustacean rich in phospholipids. Krill oil significantly reduces total cholesterol, LDL, and triglycerides, and increase HDL levels and has been found to be effective in the management of hyperlipidemia and long-term regulation of blood lipids. The aim of this study is to compare the Efficacy and Safety of a combination therapy of statin and krill oil versus Statin and Niacin in dyslipidemia. Methods: 30 eligible patients were randomized in a 12 week, open-label, comparative (2-arm, 1:1), prospective study into 2 arms, the first receiving atorvastatin 10mg od and krill oil 500mg bid and the second receiving atorvastatin 10mg od and niacin 375mg od. The primary endpoint of the study was a comparative assessment of change in lipid profile (LDL, TG, HDL) from baseline and after 12 weeks. The secondary endpoint involved recording all the adverse effects during the study. Results: Analysis of the baseline and post 12 week lipid levels by non-parametric unpaired 't' test (Mann-Whitney test) showed a statistically significant change in two of the lipid levels (i.e. LDL - p=0.0037 in favour of statin and niacin and HDL - p=0.0003 in favour of statin and niacin). However the triglyceride levels showed no significant change in the two groups (p=0.2452). Conclusions: In our study the conventional combination therapy of statin and niacin is found to be more efficacious than the newer statin and krill oil combination in lowering LDL levels and increasing HDL levels in dyslipidemic patients. A further study with a higher sample size could confirm the findings of this study.
机译:背景:动脉粥样硬化性心血管疾病是一个主要的健康问题,CAD是导致死亡的主要原因。流行病学数据将高CAD风险与总胆固醇和LDL胆固醇升高以及HDL胆固醇低水平密切相关。通常需要组合疗法以达到多种脂质治疗目标,并且低密度脂蛋白降低≥50%。烟酸/他汀类药物联合治疗可能会在数个高风险患者人群中提高OLV的成本效益。磷虾油是从南极磷虾(Euphausia superba)中提取的,磷虾是一种富含磷脂的浮游动物甲壳类动物。磷虾油可显着降低总胆固醇,低密度脂蛋白和甘油三酸酯,并增加高密度脂蛋白水平,已被发现可有效控制高脂血症和长期调节血脂。这项研究的目的是比较他汀类药物和磷虾油与他汀和烟酸联合治疗血脂异常的疗效和安全性。方法:将30名合格患者随机分为12周,进行开放标签,比较(2组,1:1),前瞻性研究,分为2组,第一组接受阿托伐他汀10mg od和磷虾油500mg bid,第二组接受阿托伐他汀10mg od和烟酸375mg od。该研究的主要终点是从基线到12周后血脂变化(LDL,TG,HDL)的比较评估。次要终点涉及记录研究期间的所有不良反应。结果:通过非参数非配对“ t”检验(Mann-Whitney检验)对基线和12周后血脂水平的分析显示,两个血脂水平(即LDL-p = 0.0037有利于他汀类药物和烟酸和HDL-p = 0.0003(赞成他汀和烟酸)。但是,甘油三酯水平在两组中均无显着变化(p = 0.2452)。结论:在我们的研究中,他汀类药物和烟酸的常规联合治疗在降低血脂异常患者的LDL水平和增加HDL水平方面比新型他汀类药物和磷虾油联合治疗更有效。更大样本量的进一步研究可以证实这项研究的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号